Table 1.
Patient characteristics.
| Characteristics | Tamsulosin (n = 49) | Silodosin (n = 32) | Naftopidil (n = 35) | P value |
|---|---|---|---|---|
| Age (y) | ||||
| Mean | 68.9 | 66.4 | 68.7 | NS |
| Range | 58–82 | 54–80 | 54–77 | |
| PSA at biopsy (ng/mL) | ||||
| Mean | 12.0 | 11.3 | 8.2 | NS |
| Range | 3.1–61.9 | 3.1–88.9 | 3.0–36.4 | |
| Gleason sum | ||||
| Mean | 6.7* | 7 | 7.3* | 0.05* |
| Range | 3–9 | 6–9 | 6–9 | |
| Prostate volume at BT (cc) | ||||
| Mean | 28.4 | 27.4 | 31 | NS |
| Range | 13.9–54.5 | 14.2–46.1 | 18.2–48.6 | |
| IPSS before treatment | ||||
| Mean | 9.9 | 9.4 | 8.8 | NS |
| Range | 1–32 | 0–29 | 0–25 | |
| Neoadjuvant HT | ||||
| Yes | 22 | 9 | 14 | |
| No | 27 | 23 | 21 | |
| Number of seeds | ||||
| Mean | 67.6 | 69.4 | 72.9 | NS |
| Range | 30–95 | 45–95 | 55–95 | |
| EBRT | ||||
| Yes | 26 | 23 | 22 | |
| No | 23 | 9 | 13 | |
| Risk category | ||||
| Low risk | 15 | 7 | 2 | |
| Intermediate risk | 14 | 15 | 20 | |
| High risk | 20 | 10 | 13 |
PSA: prostatic specific antigen; BT: brachytherapy; IPSS: International Prostate Symptoms Score; HT: hor-mone therapy; EBRT: external beam radiation threrapy.
*Tamsulosin versus naftopidil; 6.7 versus 7.3, P < 0.05.